



## Oncogenes in Cancer

Guest Editor:

**Dr. Ignacio Gil-Bazo**  
Universidad de Navarra,  
Pamplona, Spain

Deadline for manuscript  
submissions:  
**closed (31 October 2021)**

### Message from the Guest Editor

Dear Colleagues,

The first oncogenes were discovered more than three decades ago. Since then, a remarkable development has been achieved by the scientific community in order to unravel the biological impact of those oncogenes in the development and progression of different neoplasms and their potential clinical applicability in designing targeted therapies. All this knowledge has made it possible to think of a personalized treatment of cancer.

In this Special Issue entitled “Oncogenes in Cancer”, we approach the role of actionable genomic somatic alterations able to driver different solid tumors, their biological context, and the different therapeutic strategies evaluated.

This Special Issue has being conceived as a comprehensive review of the most frequently present oncogenes in major solid malignancies, updating the most relevant advances leading to the development and eventual approval of new targeted therapeutic compounds.

Dr. Ignacio Gil-Bazo  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)